RxDoctor Payments Data

Elisa Mulcahy, MD

Internal Medicine · Brockton, MANPI 1952397176

Payments from drug & device makers

$5,831in general payments, 2019–2025

Across 317 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$721
  • AstraZeneca$642
  • AbbVie$575
  • Amgen$473
  • Pfizer$463
  • Boehringer Ingelheim$365
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,831 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$210,424
Medicare patients
399
Services billed
3,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$165,541
EliquisApixaban144$159,138
JardianceEmpagliflozin90$93,694
TrulicityDulaglutide51$60,032
JanuviaSitagliptin Phosphate37$50,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$50,148
XifaxanRifaximin15$48,277
RybelsusSemaglutide23$37,415
FarxigaDapagliflozin Propanediol37$36,081
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr56$30,396
GemtesaVibegron25$28,332
Tresiba Flextouch U-200Insulin Degludec13$25,818
Tresiba Flextouch U-100Insulin Degludec31$25,245
OxycontinOxycodone Hcl29$18,128
MounjaroTirzepatide11$11,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$721$202,956158 claims
PfizerEliquis$463$159,138144 claims
Boehringer IngelheimJardiance$365$93,69490 claims
GSKTrelegy Ellipta, Anoro Ellipta$286$80,54499 claims
Lilly USA, LLCTrulicity, Mounjaro$265$71,23262 claims
MerckJanuvia$180$50,80837 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$94$48,27715 claims
AstraZenecaFarxiga$642$36,08137 claims
Sumitomo Pharma America, Inc.Gemtesa$206$28,33225 claims
AbbVieRestasis, Synthroid$575$12,51158 claims
NovartisEntresto$181$8,76713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →